Smokers with a genetic predisposition to autoimmune disorders are at an increased risk of several diseases, including rheumatoid arthritis, Crohns disease, bacterial meningitis, postsurgical infection, and cancers
Nicotine Science and Policy
November 2, 2011 - A new FDA adverse events study entitled "Suicidal Behavior and Depression in Smoking Cessation Treatments" identified "3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement." It concluded that, "The findings for varenicline, combined with other problems with its safety profile, render it unsuitable for first-line use in smoking cessation." November 24, 2011 - The FDA issues a "Safety Announcement" that although new hospitalization study of risk of neuropsychiatric adverse events found no difference between Chantix and NRT, that the study does "not rule out an increased risk of other neuropsychiatric events with Chantix." For example, obviously, a person successful at suicide is not normally hospitalized
The Plan added $118 million in FY 2026, $121 million in FY 2027, $129 million in FY 2028, and $137 million in FY 2029 for HIP-HMO and other non GHI-CBP members, approximately 25 percent of all contracts/members
Long-term use should be approached with caution due to potential health risks such as dependency, cardiovascular issues, and metabolic irregularities
